Received May 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
No adverse event; patient formerly received MMRII and VARIVAX at another clinic on 2/1/2024,; This spontaneous report was received from a medical assistant on 13-MAY-2025 and refers to a 4-year-old male patient. The patient's medical, concurrent conditions and concomitant therapies were not reported. On 01-FEB-2024, the patient was vaccinated at the same time with a dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (dose, dose number, anatomical location, route of administration, lot # and expiration date were not reported) , sterile diluent (MERCK STERILE DILUENT) (dose, dose number, anatomical location, route of administration, lot # and expiration date were not reported) , Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) ) (dose, dose number, anatomical location, route of administration, lot # and expiration date were not reported) and sterile diluent (MERCK STERILE DILUENT) (dose, dose number, anatomical location, route of administration, lot # and expiration date were not reported) for prophylaxis (Inappropriate schedule of product administration). No additional adverse event or PQC was reported. This is one of several report for the same patient (case #: 2286272).